Form D · Biotechnology
Pulmotherapeutics Inc
Tyler, TX · CIK 0002064557
Offering snapshot reported Apr 14, 2025 · SEC filing
- Reported sold
- $500K Indefinite offering
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Mar 27, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 14, 2025 | Initial | $500,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $25K (estimated)
- Finders' fees
- $25K (estimated)
- Form D file number
- 021-543536
2.5% performance-based bonus per $1,000,000 raised
Source: Form D, filed Apr 14, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nagarjun Konduru Venkata | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
714 Huntwick Ln
Tyler, TX, 75703
Tyler, TX, 75703